Clinical trials: Drug-Drug Interaction (DDI)
Male, Healthy Normal Subjects
Rifampin Drug-Drug Interaction Study With Lurasidone HCl
The effect of rifampin on the pharmacokinetics of lurasidone
- Trial name
- NCT01082276
- Testing
- Lurasidone HCl
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Healthy
A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers
A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plasma pharmacokinetics of…
- Trial name
- NCT01821066
- Testing
- PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants
This study is being done to understand how the body processes the study drug (BGB-58067) when it is taken together with other medicines. BGB-58067 is mainly broken down in the body by a liver enzyme called CYP3A.
- Trial name
- NCT07590102
- Testing
- BGB-58067, Phenytoin, Itraconazole
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Gout, Hyperuricemia
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two doses of dotinurad monotherapy, and to…
- Trial name
- NCT06056570
- Testing
- dotinurad, dotinurad + allopurinol, allopurinol
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Urica Therapeutics Inc.
Healthy Volunteer
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.
- Trial name
- NCT07438886
- Testing
- AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Healthy Volunteers
A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants
This Phase 1 study evaluates the effect of pantoprazole (a proton pump inhibitor) on the pharmacokinetics (PK) of CHF10196 (Florensocatib) in healthy male participants.
- Trial name
- NCT07683793
- Testing
- CHF10196, Pantoprazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
The purpose of this study is to assess the effect of multiple doses of ganaplacide and lumefantrine combination on the substrates of cytochrome P450 (CYP) 3A4 (midazolam), CYP2C8 (repaglinide), CYP2D6 (dextromethorphan), organic…
- Trial name
- NCT05236530
- Testing
- Midazolam, Repaglinide, Dextromethorphan
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
cMET-dysregulated Advanced Solid Tumors
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors
- Trial name
- NCT02520752
- Testing
- INC280, Midazolam, Caffeine
- Where
- 12 sites in United States, Bulgaria and 5 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteer
An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition
The study is a single-center, Phase-1, open-label, one-sequence, two-treatment period, cross-over, DDI study designed to investigate the effects of rilzabrutinib on the PK of digoxin (as P-gp substrate) and of rosuvastatin (as…
- Trial name
- NCT07855250
- Testing
- Rilzabrutinib, Rosuvastatin, Digoxin
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B.
- Trial name
- NCT06491550
- Testing
- AZD4144- Part A, AZD4144- Part B, Rosuvastatin and Furosemide- Part C
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178
A study that evaluates the interaction in healthy subjects of the heart drug Digoxin on YM178, when the latter is taken on a continuous basis, in order to establish that there is no risk to patients who may take this combination…
- Trial name
- NCT01663961
- Testing
- YM178 OCAS, Digoxin
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Volunteer
Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor
An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower content tablets and the pharmacokinetics of…
- Trial name
- MT-7117 BA DDI (NCT03688022)
- Testing
- MT-7117, PPI, Acidic beverage
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Healthy Volunteers
Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects
Study of a drug drug interaction between Paroxetine and PF-00299804.
- Trial name
- NCT01318031
- Testing
- Period 1, Period 2
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
This is a Phase 1, single-center, multi-arm, open-label, randomized, three-period, crossover study to evaluate the drug-drug interaction, pharmacokinetics, safety, and tolerability of a single dose of SPR741 combined with each of…
- Trial name
- NCT03376529
- Testing
- SPR741, Ceftazidime, Piperacillin/tazobactam
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Alzheimer Disease
Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
The purpose of the study is to determine if the concomitant administration of either ketoconazole or fluconazole with BMS-708163 will affect the PK of BMS-708163 and to assess safety and tolerability of BMS-708163
- Trial name
- NCT00860275
- Testing
- BMS-708163, BMS-708163 + Ketoconazole, Ketoconazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
A Phase I, Open-label, Fixed-Sequence Study to Evaluate the Effect of Multiple-dose Itraconazole or Rifampicin Capsules on the Single-dose PK Profiles of IMP4297 Capsules in Healthy Subjects
- Trial name
- NCT04584515
- Testing
- IMP4297 40 mg, IMP4297 100 mg
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Impact Therapeutics, Inc.
DDI (Drug-Drug Interaction)
Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants.
This study adopts a single-center, open-label, same-subject sequential crossover clinical trial design, aiming to evaluate the effects of oral administration of rifampicin or itraconazole on the pharmacokinetic profiles of…
- Trial name
- NCT07809815
- Testing
- Befotertinib and rifampicin, Befotertinib and itraconazole
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Healthy
A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants
This is a Phase 1, fixed sequence, multiple dose, open label study of the effect of PF-06826647 on oral contraceptive (OC) pharmacokinetics (PK) and vice versa in healthy female participants.
- Trial name
- NCT04134715
- Testing
- PF-06826647, Oral Contraceptive (OC)
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes
The DDI Study of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between multiple oral doses of SP2086 and a single oral dose of Simvastatin in healthy adult volunteers.
- Trial name
- NCT02817243
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type II
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and sitagliptin in healthy male volunteers.
- Trial name
- NCT02824874
- Testing
- Duvie Tab. 0.5mg, Duvie Tab. 0.5mg + Januvia Tab. 100mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical